Advanced in WT1-Related Wilms Tumor Syndromes

Dr. Robert M. Rifkin

Hematology Oncology | Hematology | Oncology
UCHealth
Yampa Valley Medical Center
1100 Central Park Dr, 
Steamboat Springs, CO 
Accepting New Patients
43 Years of Experience

Advanced in WT1-Related Wilms Tumor Syndromes
UCHealth
Yampa Valley Medical Center
1100 Central Park Dr, 
Steamboat Springs, CO 
OverviewInsuranceLocationsClinical ResearchSimilar Doctors

Overview

Robert Rifkin is a Hematologist Oncology specialist and a Hematologist in Steamboat Springs, Colorado. Dr. Rifkin has been practicing medicine for over 43 years and is rated as an Advanced provider by MediFind in the treatment of WT1-Related Wilms Tumor Syndromes. His top areas of expertise are Multiple Myeloma, Febrile Neutropenia, Agranulocytosis, Bone Tumor, and Bone Marrow Transplant. Dr. Rifkin is currently accepting new patients.

His clinical research consists of co-authoring 70 peer reviewed articles and participating in 6 clinical trials. MediFind looks at clinical research from the past 15 years.

Graduate Year
1982
Specialties
Hematology Oncology
Hematology
Oncology
Licenses
Internal Medicine in CO
Hospital Affiliations
Hca Healthone Rose
Hca Healthone Presbyterian St Lukes
Uchealth Yampa Valley Medical Center
Languages Spoken
English
Gender
Male

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Aetna
  • EPO
  • HMO
  • POS
  • PPO
Anthem
  • EPO
  • HMO
  • POS
  • PPO
Blue Cross Blue Shield
  • EPO
  • HMO
  • POS
  • PPO
Blue Shield of California
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE-MEDICAID PLAN
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
  • PPO
Change Healthcare
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
Cigna
  • EPO
  • HMO
  • PPO
Denver Health Medical Plan
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
Farm Bureau Health Plans
  • HMO
  • MEDICARE MAPD
  • MEDICARE PDP
Health Care Services Corporation
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
  • PPO
Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
Managed Medicaid
  • OTHER MANAGED MEDICAID
Medicaid
  • OTHER MEDICAID
  • STATE MEDICAID
Silversummit Health Plan
  • HMO
  • MANAGED MEDICAID PLAN
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO
Walgreens
  • MEDICARE DISCOUNT CARD
  • MEDICARE PDP
  • OTHER MEDICARE
Wellcare
  • EPO
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
View 11 Less Insurance Carriers -

Locations

YAMPA VALLEY MEDICAL CENTER
1100 Central Park Dr, Steamboat Springs, CO 80487
Call: 303-388-4876
Other Locations
ROCKY MOUNTAIN CANCER CENTERS LLP
1800 Williams St, Suite 200, Denver, CO 80218
Call: 303-388-4876

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.


6 Clinical Trials

A Phase III, Open-Label, Randomized Study to Evaluate the Efficacy and Safety of Single Agent Belantamab Mafodotin Compared to Pomalidomide Plus Lowdose Dexamethasone (Pom/Dex) in Participants With Relapsed/Refractory Multiple Myeloma (RRMM) (DREAMM 3)
A Phase III, Open-Label, Randomized Study to Evaluate the Efficacy and Safety of Single Agent Belantamab Mafodotin Compared to Pomalidomide Plus Lowdose Dexamethasone (Pom/Dex) in Participants With Relapsed/Refractory Multiple Myeloma (RRMM) (DREAMM 3)
Enrollment Status: Active_not_recruiting
Publish Date: June 10, 2025
Intervention Type: Drug
Study Drugs: Belantamab Mafodotin, Pom/Dex (Pomalidomide plus Low Dose Dexamethasone)
Study Phase: Phase 3
An Open-Label, Single-Arm, Multicenter Study to Evaluate the Effectiveness and Safety of Ixazomib (NINLARO®) in Combination With Lenalidomide and Dexamethasone (IRD) in Patients With Multiple Myeloma Previously Receiving a Bortezomib-Based Induction Regimen (US MM-6)
An Open-Label, Single-Arm, Multicenter Study to Evaluate the Effectiveness and Safety of Ixazomib (NINLARO®) in Combination With Lenalidomide and Dexamethasone (IRD) in Patients With Multiple Myeloma Previously Receiving a Bortezomib-Based Induction Regimen (US MM-6)
Enrollment Status: Active_not_recruiting
Publish Date: March 28, 2025
Intervention Type: Drug
Study Drugs: Ixazomib, Lenalidomide, Dexamethasone
Study Phase: Phase 4
A Phase II Trial of Daratumumab, Lenalidomide and Dexamethasone (DRd) in Combination With Selinexor for Patients With Newly Diagnosed Multiple Myeloma
A Phase II Trial of Daratumumab, Lenalidomide and Dexamethasone (DRd) in Combination With Selinexor for Patients With Newly Diagnosed Multiple Myeloma
Enrollment Status: Active_not_recruiting
Publish Date: January 16, 2025
Intervention Type: Drug
Study Drugs: Selinexor, Dexamethasone Oral, Daratumumab, Lenalidomide
Study Phase: Phase 2
A Phase 1 Study of SEA-BCMA in Patients With Relapsed or Refractory Multiple Myeloma
A Phase 1 Study of SEA-BCMA in Patients With Relapsed or Refractory Multiple Myeloma
Enrollment Status: Terminated
Publish Date: December 24, 2024
Intervention Type: Drug
Study Drugs: SEA-BCMA, Dexamethasone, Pomalidomide
Study Phase: Phase 1
DREAMM 7: A Multicenter, Open-Label, Randomized Phase III Study to Evaluate the Efficacy and Safety of the Combination of Belantamab Mafodotin, Bortezomib, and Dexamethasone (B-Vd) Compared With the Combination of Daratumumab, Bortezomib and Dexamethasone (D-Vd) in Participants With Relapsed/Refractory Multiple Myeloma
DREAMM 7: A Multicenter, Open-Label, Randomized Phase III Study to Evaluate the Efficacy and Safety of the Combination of Belantamab Mafodotin, Bortezomib, and Dexamethasone (B-Vd) Compared With the Combination of Daratumumab, Bortezomib and Dexamethasone (D-Vd) in Participants With Relapsed/Refractory Multiple Myeloma
Enrollment Status: Active_not_recruiting
Publish Date: October 24, 2024
Intervention Type: Drug
Study Drugs: Belantamab Mafodotin, Daratumumab, Bortezomib, Dexamethasone
Study Phase: Phase 3
A Phase 1/2a Dose-Finding Study of PT-112 in Patients With Relapsed or Refractory Multiple Myeloma
A Phase 1/2a Dose-Finding Study of PT-112 in Patients With Relapsed or Refractory Multiple Myeloma
Enrollment Status: Completed
Publish Date: April 26, 2022
Intervention Type: Drug
Study Drug: PT-112
Study Phase: Phase 1
View 5 Less Clinical Trials

70 Total Publications

Belantamab mafodotin plus bortezomib and dexamethasone in patients with relapsed or refractory multiple myeloma (DREAMM-7): updated overall survival analysis from a global, randomised, open-label, phase 3 trial.
Belantamab mafodotin plus bortezomib and dexamethasone in patients with relapsed or refractory multiple myeloma (DREAMM-7): updated overall survival analysis from a global, randomised, open-label, phase 3 trial.
Journal: The Lancet. Oncology
Published: April 28, 2025
View All 70 Publications
Similar Doctors
Experienced in WT1-Related Wilms Tumor Syndromes
Dr. Alexander T. Urquhart
Oncology | Hematology
Experienced in WT1-Related Wilms Tumor Syndromes
Dr. Alexander T. Urquhart
Oncology | Hematology

Vail Clinic Inc

322 Beard Creek Rd, 
Edwards, CO 
 (57.3 miles away)
970-569-7622
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Alexander Urquhart is an Oncologist and a Hematologist in Edwards, Colorado. Dr. Urquhart is rated as a Distinguished provider by MediFind in the treatment of WT1-Related Wilms Tumor Syndromes. His top areas of expertise are Chronic Lymphocytic Leukemia (CLL), Ovarian Carcinosarcoma, Virilizing Ovarian Tumor, and Testicular Yolk Sac Tumor.

VIEW MORE WT1-RELATED WILMS TUMOR SYNDROMES DOCTORS

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Rifkin's expertise for a condition
ConditionClose
  • Elite
  • Multiple Myeloma
    Dr. Rifkin is
    Elite
    . Learn about Multiple Myeloma.
    See more Multiple Myeloma experts
  • Distinguished
  • Agranulocytosis
    Dr. Rifkin is
    Distinguished
    . Learn about Agranulocytosis.
    See more Agranulocytosis experts
  • Bone Tumor
    Dr. Rifkin is
    Distinguished
    . Learn about Bone Tumor.
    See more Bone Tumor experts
  • Chronic B-Cell Leukemia (CBCL)
    Dr. Rifkin is
    Distinguished
    . Learn about Chronic B-Cell Leukemia (CBCL).
    See more Chronic B-Cell Leukemia (CBCL) experts
  • Chronic Lymphocytic Leukemia (CLL)
    Dr. Rifkin is
    Distinguished
    . Learn about Chronic Lymphocytic Leukemia (CLL).
    See more Chronic Lymphocytic Leukemia (CLL) experts
  • Diffuse Large B-Cell Lymphoma (DLBCL)
    Dr. Rifkin is
    Distinguished
    . Learn about Diffuse Large B-Cell Lymphoma (DLBCL).
    See more Diffuse Large B-Cell Lymphoma (DLBCL) experts
  • Essential Thrombocythemia
    Dr. Rifkin is
    Distinguished
    . Learn about Essential Thrombocythemia.
    See more Essential Thrombocythemia experts
View All 14 Distinguished Conditions
  • Advanced
  • Acute Monoblastic Leukemia (AmoL)
    Dr. Rifkin is
    Advanced
    . Learn about Acute Monoblastic Leukemia (AmoL).
    See more Acute Monoblastic Leukemia (AmoL) experts
  • Acute Mountain Sickness
    Dr. Rifkin is
    Advanced
    . Learn about Acute Mountain Sickness.
    See more Acute Mountain Sickness experts
  • Acute Myeloblastic Leukemia with Maturation
    Dr. Rifkin is
    Advanced
    . Learn about Acute Myeloblastic Leukemia with Maturation.
    See more Acute Myeloblastic Leukemia with Maturation experts
  • Acute Myeloblastic Leukemia without Maturation
    Dr. Rifkin is
    Advanced
    . Learn about Acute Myeloblastic Leukemia without Maturation.
    See more Acute Myeloblastic Leukemia without Maturation experts
  • Acute Myeloid Leukemia (AML)
    Dr. Rifkin is
    Advanced
    . Learn about Acute Myeloid Leukemia (AML).
    See more Acute Myeloid Leukemia (AML) experts
  • Adult Immune Thrombocytopenia
    Dr. Rifkin is
    Advanced
    . Learn about Adult Immune Thrombocytopenia.
    See more Adult Immune Thrombocytopenia experts
View All 88 Advanced Conditions
  • Experienced
  • Acute Eosinophilic Pneumonia
    Dr. Rifkin is
    Experienced
    . Learn about Acute Eosinophilic Pneumonia.
    See more Acute Eosinophilic Pneumonia experts
  • Acute Lymphoblastic Leukemia (ALL)
    Dr. Rifkin is
    Experienced
    . Learn about Acute Lymphoblastic Leukemia (ALL).
    See more Acute Lymphoblastic Leukemia (ALL) experts
  • Acute Myelomonocytic Leukemia
    Dr. Rifkin is
    Experienced
    . Learn about Acute Myelomonocytic Leukemia.
    See more Acute Myelomonocytic Leukemia experts
  • Acute Promyelocytic Leukemia
    Dr. Rifkin is
    Experienced
    . Learn about Acute Promyelocytic Leukemia.
    See more Acute Promyelocytic Leukemia experts
  • Adrenal Cancer
    Dr. Rifkin is
    Experienced
    . Learn about Adrenal Cancer.
    See more Adrenal Cancer experts
  • Adrenocortical Carcinoma
    Dr. Rifkin is
    Experienced
    . Learn about Adrenocortical Carcinoma.
    See more Adrenocortical Carcinoma experts
View All 170 Experienced Conditions
Want to save this doctor for later?
Sign Up
Is this your doctor?
Find A Second Opinion
Not sure about your diagnosis?
Check Your Symptoms
 
 
 
 
Learn about our expert tiers
Learn More
Are you the provider on this profile?
Claim Profile
For Patients
  • Our Story
  • How MediFind Works
  • Conditions A-Z
  • Doctor Directory
  • Symptoms Directory
  • Procedures Directory
  • Treatment Directory
  • Drug Directory
  • Infusion Center Finder
  • FAQ
  • Contact Us
For Providers and Practices
  • Claim Your Profile
  • Newsroom
Business Solutions
  • Provider
  • Network Solutions
Additional Resources
  • Consumer Health Data Privacy Policy
  • Privacy Policy
  • Terms of Use
  • Advertising Policy
  • Content Policy
Subscribe to our newsletter

Sign up to stay informed about MediFind and get wellness sent your way.

Close

    By subscribing, I agree to MediFind's Terms of Use, Privacy Policy and Consumer Health Data Privacy Policy, as applicable.

    Bullet PinMediFind
    Follow us on
    This information is not intended as a substitute for informed medical advice. You should work with a licensed professional to diagnose and treat health conditions. We let the data speak for itself, MediFind does not endorse any healthcare providers.
    © 2025 All Rights Reserved